| 2007-007847-28 (Universitätsklinikum Erlangen-DE) (DERMA-ER-DC08) |
A multicenter, randomized, two-armed, open-label phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous dendritic cells versus observation of patients with resected mel….. |
2011-09-16 |
Uveal melanoma |
| 2015-005322-19 (Radboud University Nijmegen Medical Centre-NL) (MIND-DC) |
A randomized, double-blind, placebo-controlled phase III study to evaluate active immunization in adjuvant therapy of patients with stage IIIB and IIIC melanoma with natural dendritic cells pulsed... |
2016-01-21 |
Melanoma with regional lymph nodes metastases (stage III) |
| 2012-001410-41 (Istituto Scientifico Romagnolo per lo studio e la cura dei tumori-IT) (IRST172.02) |
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastati... |
2013-05-30 |
Metastatic melanoma |
| 2009-015737-73 (Radboud University Nijmegen Medical Centre-NL) (2009-015737-73) |
Single-step antigen loading and TLR activation of dendritic cells by mRNA electroporation for vaccination in stage III and IV melanoma patients |
2010-02-04 |
Melanoma patients expressing gp100 and tyrosinase |
| 2008-001973-14 (Radboud University Nijmegen Medical Centre-NL) (KUN2006-3699) |
TLR ligand matured dendritic cell vaccination in melanoma patients: the key towards a more potent immune induction? |
2009-04-27 |
HLA-A2.1 positive melanoma patients expressing gp100 and tyrosinase |
| 2008-001974-33 (Radboud University Nijmegen Medical Centre-NL) (08/014) |
mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patients |
2009-04-14 |
HLA-A2.1 positive patients at high risk of uveal melanoma, expressing gp100 and tyrosinase |
| 2010-020228-23 (Radboud University Nijmegen Medical Centre-NL) (NL32381.000.10) |
Immunochemotherapy: do platin-based chemotherapeutics enhance dendritic cell vaccine efficacy in melanoma patients? |
2010-12-21 |
Melanoma patients expressing gp100 and tyrosinase |
| 2010-023058-35 (UZ Brussel-BE) (UZB-VUB-10-001) |
A two-stage phase II study of autologous TriMix-DC therapeutic vaccine in combination with ipilimumab in patients with previously treated unresectable stage III or IV melanoma |
2011-01-04 |
Previously treated unresectable stage III or IV melanoma |
| 2005-002636-97 (Immuno-Designed Molecules-GB) (DC-MEL-203) |
An open-label, phase II study of matured dendritic cells pulsed ex vivo with 3 melanoma cell line lysates (IDD-3) with or without peginterferon alpha-2b (PegIFN-a 2b) in patients with resected sta... |
2005-09-19 |
Patients with cutaneous melanoma (stage IIc, IIIb, IIIc) |
| 2011-001410-33 (UZ Brussel-BE) (UZB-VUB-11-01) |
Randomized phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment o... |
2016-03-10 |
Stage III/IV melanoma free of measurable tumour lesions |
| 2011-001474-25 (Klinik für Dermatologie, Venerologie und Allergologie; Charité-Universitätsmedizin Berlin-DE) (SVM9122) |
A single-centre, single arm, open-label, exploratory trial of interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node disse... |
2012-01-02 |
Melanoma patients stage III |
| 2006-005238-19 (Instituto Cientifico y Tecnologico de Navarra-ES) |
Phase II study with immunotherapy with dendritic cells and tumour infiltrating lymphocytes in solid tumours |
2007-07-26 |
Melanoma, renal carcinoma, hepatocarcinoma |
|
NCT01753089 (Dana Farber Harvard Center-USA) (12-306, NCI-2013-01799, NCT01753089) |
Dendritic cell activating scaffold in melanoma, immunotherapy (vaccine), dendritic cell (phase I) |
2012-12-17 |
Melanoma with recurrent stage IIIC or with stage IV |
|
NCT02334735 (Icahn School of Medicine at Mount Sinai-USA) |
A comparison of matured dendritic cells and montanide® in study subjects with high risk of melanoma recurrence (phase II) |
2015-01-06 (recruiting) |
Melanoma stages IIB-IV |
